Literature DB >> 24926071

JAK inhibitors: a home run for GVHD patients?

Takanori Teshima1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24926071     DOI： 10.1182/blood-2014-04-570325

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

Review 1.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

3.  Update of humanized animal disease models in studying Graft-versus-host disease.

Authors:  Feng Huang; Feng Lin Cao; Song Guo Zheng
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

4.  Ruxolitinib treatment for GvHD in patients with myelofibrosis.

Authors:  Y Mori; K Ikeda; T Inomata; G Yoshimoto; N Fujii; H Ago; T Teshima
Journal:  Bone Marrow Transplant       Date:  2016-10-10       Impact factor: 5.483

Review 5.  Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape.

Authors:  Hildegard T Greinix; Francis Ayuk; Robert Zeiser
Journal:  Leukemia       Date:  2022-09-24       Impact factor: 12.883

Review 6.  The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models.

Authors:  Takanori Teshima; Geoffrey R Hill
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 8.786

7.  Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.

Authors:  Alfonso Rodríguez-Gil; Virginia Escamilla-Gómez; Melanie Nufer; Félix Andújar-Sánchez; Teresa Lopes-Ramos; José Antonio Bejarano-García; Estefanía García-Guerrero; Cristina Calderón-Cabrera; Teresa Caballero-Velázquez; Clara Beatriz García-Calderón; Paola Hernández-Díaz; Juan Luis Reguera-Ortega; Nancy Rodríguez-Torres; Nuria Martínez-Cibrián; José Ignacio Rodríguez-Barbosa; Javier Villadiego; José Antonio Pérez-Simón
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

8.  TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.

Authors:  Ayako Kobayashi; Shinichi Kobayashi; Kosuke Miyai; Yukiko Osawa; Toshikatsu Horiuchi; Shoichiro Kato; Takaaki Maekawa; Takeshi Yamamura; Junichi Watanabe; Ken Sato; Hitoshi Tsuda; Fumihiko Kimura
Journal:  Int J Hematol       Date:  2017-10-12       Impact factor: 2.490

9.  Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.

Authors:  Virginia Escamilla Gómez; Valentín García-Gutiérrez; Lucía López Corral; Irene García Cadenas; Ariadna Pérez Martínez; Francisco J Márquez Malaver; Teresa Caballero-Velázquez; Pedro A González Sierra; María C Viguria Alegría; Ingrid M Parra Salinas; Cristina Calderón Cabrera; Marta González Vicent; Nancy Rodríguez Torres; Rocío Parody Porras; Christelle Ferra Coll; Guillermo Orti; David Valcárcel Ferreiras; Rafael De la Cámara LLanzá; Paula Molés; Kyra Velázquez-Kennedy; María João Mende; Dolores Caballero Barrigón; Estefanía Pérez; Rodrigo Martino Bofarull; Silvanna Saavedra Gerosa; Jorge Sierra; Marc Poch; María T Zudaire Ripa; Miguel A Díaz Pérez; Blanca Molina Angulo; Isabel Sánchez Ortega; Jaime Sanz Caballer; Juan Montoro Gómez; Ildefonso Espigado Tocino; José A Pérez-Simón
Journal:  Bone Marrow Transplant       Date:  2019-11-07       Impact factor: 5.483

10.  Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.

Authors:  Enrico Maffini; Luisa Giaccone; Moreno Festuccia; Lucia Brunello; Ilaria Buondonno; Dario Ferrero; Mario Boccadoro; Chiara Dellacasa; Alessandro Busca; Domenico Novero; Benedetto Bruno
Journal:  J Hematol Oncol       Date:  2016-08-08       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.